Boundless Bio is in a bind. A phase 1/2 trial has revealed the shortcomings of Boundless’ lead candidate, prompting the ...

The adjustment follows a reassessment of the company’s lead CHK1 inhibitor program and its potential in the oncology market. Leerink Partners’ decision is based on the recent shift in ...

Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin ...

In further tests, the method was applied to proteins with essential cellular functions, including the transcription factor c-Myc and the kinase Chk1. Specific protein segments were temporarily ...

Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first ha ...

Discontinuing current monotherapy and combination arms of BBI-355 in POTENTIATE clinical trial Boundless has been investigating BBI-355, a novel, oral, selective CHK1 inhibitor designed to target ...

BBI-355 and BBI-825 Programs Discontinuing current monotherapy and combination arms of BBI-355 in POTENTIATE clinical trial Boundless has been investigating BBI-355, a novel, oral, selective CHK1 ...

Here we demonstrate that ARF induces the ATR‐ and Chk1‐dependent phosphorylation of the RelA transactivation domain at threonine 505, a site required for ARF‐dependent repression of RelA ...